Mechanism of Action

Multivesicular liposomes

Multivesicular liposomes

The extended-release bupivacaine technology used in NOCITA® (bupivacaine liposome injectable suspension) consists of multivesicular liposomes composed of hundreds to thousands of chambers per particle, encapsulating aqueous bupivacaine.

Honeycomb matrix

The liposomes are microscopic structures made of nonconcentric lipid bilayers resembling a honeycomb-like matrix and are designed to allow bupivacaine to gradually release from vesicles over a period of time.

View the NOCITA Mechanism of Action

Clinical Support

Your convenient one-stop source for viewing, downloading and sharing important information.

Learn more >


Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

NOCITA is now available.

“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results.  The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively.  Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications.  Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.” 

Veterinary Surgeon

Milwaukee WI

Other therapeutics from Aratana






ENTYCE® (capromorelin oral solution)
provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE® provides safe, effective appetite stimulation.


IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.